clinical trial · NCT06572397
Open-Label Study of Safety of H1337 in Healthy Volunteers
D. Western Therapeutics Institute, Inc.·phase1·completed·n = 17
Glaucoma Open-Angle PrimaryOcular HypertensionH-1337 1.0%
brief summary
The trial will evaluate the safety of one dose regimen of H-1337 \[1% twice daily (b.i.d.)\] in both eyes in healthy volunteers.
started
Sep 16, 2024
primary completion
Oct 14, 2024
completion
Oct 14, 2024
last updated
Feb 11, 2025
official title
An Open-Label Study Assessing the Ocular and Systemic Safety and Systemic Absorption of H1337 Ophthalmic Solution, 1% in Healthy Volunteers
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol